ReviewAnnals of translational medicine2015
MicroRNAs in multiple myeloma and related bone disease.
Review in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.Scientific reports · 2016Pooled it
- Integrated analysis of miR-15a-5p, miR-20a-5p, and miR-33b-3p identifies EGR2-associated biomarkers in multiple myeloma.BMC cancer · 2026Article
- The Role of microRNAs in Gene Expression and Signaling Response of Tumor Cells to an Acidic Environment.International journal of molecular sciences · 2023Article
- Review
- Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma.International journal of molecular sciences · 2022Article
- Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways.Bioinformatics and biology insights · 2022Article
- Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression.Cancers · 2021Review
- Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.Cells · 2021Review
- MicroRNA-98-5p prevents bone regeneration by targeting high mobility group AT-Hook 2.Experimental and therapeutic medicine · 2019Article
- MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6.Experimental and therapeutic medicine · 2019Article
- anamiR: integrated analysis of MicroRNA and gene expression profiling.BMC bioinformatics · 2019Article
- MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression.The Kaohsiung journal of medical sciences · 2019Article
- The biological significance of histone modifiers in multiple myeloma: clinical applications.Blood cancer journal · 2018Review
- The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma.Oncology letters · 2018Review
- MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.Current osteoporosis reports · 2017Review
- Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.Journal of hematology & oncology · 2016Article
- DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Oncotarget · 2016Review
- MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.American journal of cancer research · 2016Article
- miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are short non coding RNAs aberrantly expressed in solid and hematopoietic malignancies where they play a pivotal function as post-transcriptional regulators of gene expression. Recent reports have unveiled a central role of miRNAs in multiple myeloma onset and progression and preclinical findings are progressively disclosing their potential therapeutic value as drugs or targets. In this review, we provide the basic insights of miRNA biology and function, showing how these molecules are extensively dysregulated in malignant plasma cells (PC) and related microenvironment, thus favoring clone survival and proliferation. We here describe how these critical activities have recently been evaluated to design miRNA-based therapies against multiple myeloma cells and its surrounding microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.